Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop tegasorb supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

Tegasorb: 3M Hydrocolloid Dressing Guide & Specs

Explore 3M Tegasorb hydrocolloid wound dressings: clinical mechanisms, regular vs. thin lines, FDA 510(k) clearances, CMS HCPCS coding, and procurement specs.

Written and maintained by CASRAI Editorial Board

Published

On this page

Tegasorb is a sterile, moisture-retentive hydrocolloid wound dressing manufactured by 3M (now part of Solventum) engineered for the clinical management of low- to moderately exuding partial- and full-thickness dermal wounds, including pressure ulcers, venous ulcers, donor sites, and superficial abrasions. Cleared by the FDA under 510(k) clearances K982893 and K982892, the dressing integrates an inner hydrophilic colloidal adhesive mass with an outer breathable polyurethane film backing that creates a moist healing environment, supports autolytic debridement, and provides an impermeable barrier against external fluids, bacteria, and viral pathogens.

This page describes products and general use; it is not medical advice.

Definition, Core Materials, and Regulatory Scope

Tegasorb is an advanced wound care dressing belonging to the hydrocolloid class of medical consumables. While the product was originally branded as 3M Tegasorb, 3M transitioned the packaging and catalog nomenclature into the broader Tegaderm brand family under the product title 3M Tegaderm Hydrocolloid Dressing and 3M Tegaderm Hydrocolloid Thin Dressing. Despite this packaging update, healthcare procurement managers, clinical research coordinators, and wound ostomy continence nurses routinely reference the Tegasorb trade name when specifying hydrocolloid formulations characterized by 3M’s proprietary film and adhesive matrix. In the broader taxonomy of wound management products, Tegasorb represents an occlusive to semi-occlusive primary or secondary dressing designed to maintain physiological moisture at the wound bed while protecting fragile regenerating skin from mechanical friction and exogenous microbial contamination.

The dressing consists of a multi-layer composite structure engineered with two primary functional components:

  • Inner Hydrocolloid Layer: The wound-contact adhesive mass comprises a hypoallergenic synthetic elastomeric polymer matrix embedded with hydrophilic polysaccharide particles, primarily sodium carboxymethylcellulose (NaCMC), cross-linked pectin, and gelatin. These colloidal polymers exhibit high swelling capacity upon contact with wound exudate, transforming from a tacky adhesive mass into a smooth, cohesive hydrophilic gel. This gel sheet cushions the wound bed, prevents dressing adherence to fragile epithelial buds, and maintains an optimal microenvironment for tissue repair.
  • Outer Film Backing: The exterior surface consists of a transparent polyurethane film layer identical in composition to the benchmark 3M Tegaderm transparent film. This film is semi-permeable, exhibiting a dynamic moisture vapor transmission rate (MVTR) that increases in the presence of higher wound fluid levels to facilitate controlled trans-evaporation while remaining entirely impermeable to liquid water, physiological fluids, bacteria, and viruses.

From a regulatory standpoint, the U.S. Food and Drug Administration (FDA) cleared 3M Tegasorb Hydrocolloid Dressing under 510(k) premarket notification K982893 (decision date October 26, 1998) and the low-profile Tegasorb Thin variant under K982892 (decision date October 26, 1998). Within the FDA medical device taxonomy, these dressings are classified under Product Code KMF (“Dressing, Wound, Occlusive”) regulated under 21 CFR 880.5090 and general hospital surgical review panels. For healthcare purchasers evaluating regulatory compliance, Tegasorb dressings are sterile, single-use devices categorized under FDA Class I / unclassified medical supplies that require formal 510(k) premarket substantial equivalence determinations. A detailed overview of how medical dressings are categorized across regulatory agencies is available in our analysis of what is a medical dressing.

Mechanism of Action and Biological Barrier Performance

The clinical efficacy of Tegasorb relies on the physiological principle of moist wound healing, originally established in dermal biology by George Winter. When an open cutaneous ulcer or partial-thickness wound is exposed to ambient air and allowed to dry, superficial tissue desiccation leads to eschar formation, delayed cellular migration, and localized pain caused by exposed sensory nerve endings. Tegasorb counteracts desiccation by establishing an occlusive fluid equilibrium over the wound base.

Upon application, the sodium carboxymethylcellulose and polysaccharide granules within the adhesive layer absorb water and dissolved electrolytes from wound exudate. As these hydrophilic particles hydrate, they swell tangentially and vertically, converting the inner surface into a soft, non-adherent gelatinous blanket. This physical transformation yields several distinct biological advantages:

  • Autolytic Debridement: By sealing the wound beneath a moisture-retentive barrier, Tegasorb traps endogenous wound fluids containing endogenous proteolytic enzymes (such as matrix metalloproteinases and neutrophil elastase) and macrophage-derived cytokines. These physiological enzymes break down necrotic debris, fibrin slough, and devitalized collagen fibers without causing trauma to viable granulation tissue, providing a gentle and continuous autolytic debridement process.
  • Angiogenesis and Re-Epithelialization: The hypoxic, moist microenvironment maintained beneath the occlusive dressing stimulates local angiogenic signaling pathways, encouraging capillary sprouting and healthy granulation bed development. Epithelial keratinocytes migrate up to three times faster across a moist dermal plane than beneath dry scab tissue.
  • Pain and Trauma Mitigation: Because the hydrated hydrocolloid mass does not adhere to the moist tissue of the wound bed, dressing changes do not strip newly formed capillary beds or epidermal islands. Furthermore, the fluid interface insulates free peripheral nerve endings from atmospheric exposure and mechanical irritation, substantially reducing procedural pain during dressing removal.

In addition to exudate interaction, the outer polyurethane film provides an impermeable barrier against biological contaminants. Specialized laboratory barrier testing evaluating the integrity of intact 3M film membranes demonstrates that the backing prevents the penetration of viral pathogens of 27 nanometers (nm) in diameter or larger, including Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Immunodeficiency Virus (HIV) surrogate models, provided the dressing remains sealed and free from mechanical channel leakage. For clinical facilities and laboratory staff managing infectious protocols, this viral and bacterial barrier reduces the risk of cross-contamination in busy inpatient and outpatient settings. Further details regarding the physical barrier properties of transparent films can be examined in our dedicated guide on what is Tegaderm used for.

Product Lineup: Regular vs. Thin Formulations and Shapes

The Tegasorb portfolio is engineered into two primary material formulations—Regular (Standard) and Thin—each tailored to specific wound depths, drainage levels, and anatomical application sites. Selecting the appropriate formulation is essential for optimizing wear time, preventing maceration, and minimizing supply costs.

Regular (Standard) Tegasorb Formulation

The Regular formulation features a substantial hydrocolloid mass designed for wounds producing low to moderate levels of serous or serosanguinous exudate. The added thickness of the hydrocolloid core provides mechanical cushioning, making it particularly valuable over bony prominences such as the sacrum, trochanters, and ischial tuberosities where external friction and localized shear forces threaten delicate skin. Standard Tegasorb is packaged in both bordered and non-bordered configurations. The bordered oval styles integrate an extended transparent film border beyond the hydrocolloid pad, which anchors the dressing to periwound skin, prevents edge rolling caused by bedding friction, and eliminates the need for perimeter taping.

Tegasorb Thin Formulation

Tegasorb Thin (available under catalog numbers 90021 through 90024) utilizes a streamlined, low-profile hydrocolloid matrix with approximately half the thickness of the standard dressing. The thin design provides high flexibility and conformability, adhering smoothly to challenging anatomical contours such as heels, elbows, digits, and skin folds. Because of its reduced hydrocolloid volume, Tegasorb Thin exhibits lower total fluid absorption capacity and is indicated primarily for superficial wounds with light or minimal drainage, post-operative sutured incisions, donor harvest sites, and minor skin tears. Furthermore, Tegasorb Thin is semi-translucent, allowing clinicians to inspect the peri-incisional skin and monitor the expanding exudate gel bubble without removing the dressing. It is also widely used as a prophylactic barrier over intact but fragile skin in elderly or bedbound patients to prevent frictional epidermal stripping.

Anatomical Configurations and Sourced Decision Guide

To accommodate diverse anatomical contours, 3M engineered Tegasorb into distinct geometric formats: square non-bordered sheets (which can be cut into smaller segments if needed), bordered ovals with beveled hydrocolloid edges, and a specialized sacral design featuring a contoured notch tailored to fit the gluteal cleft. The decision guide below outlines the structural and clinical differences between the two core product families based on manufacturer specifications and peer-reviewed evaluations.

Specification Parameter Tegasorb Regular (Standard) Tegasorb Thin
Hydrocolloid Pad Thickness Standard profile (approx. 1.2 mm to 1.8 mm) Ultra-thin profile (approx. 0.5 mm to 0.7 mm)
Target Exudate Volume Low to moderate wound drainage Minimal to light wound drainage
Visual Monitoring Capability Opaque tan pad; outer film border transparent Semi-translucent; wound perimeter visible
Mechanical Cushioning Substantial pressure and shear attenuation Low pressure cushioning; high friction barrier
Available Shapes Square, Bordered Oval, Sacral Contoured Square, Bordered Oval
Prophylactic Friction Use Secondary option for high-shear zones Primary standard for intact, fragile skin
Standard Packaging Count 5 dressings per box (sacral: 6 per box) 10 dressings per box

Procurement teams should note that the dataset below compiles the full spectrum of catalog item numbers, precise dimensions, inner pad surface areas, and applicable HCPCS reimbursement classifications across both product families.

Clinical Indications, Precautions, and Contraindications

Deploying Tegasorb effectively within clinical research trials and healthcare facilities requires clear adherence to manufacturer labeling and evidence-based wound care guidelines. Using occlusive hydrocolloids outside their intended indications can compromise wound healing or precipitate adverse clinical events.

FDA-Cleared Clinical Indications

Under its 510(k) labeling, Tegasorb hydrocolloid dressings are indicated for the management of the following wound types under professional medical supervision:

  • Pressure Injuries: Non-infected Stage II pressure injuries involving partial-thickness loss of the dermis, as well as shallow Stage III and IV pressure ulcers with minimal to moderate exudate once deep cavitary dead space has been addressed. Clinical protocols for applying hydrocolloid dressings on pressure ulcers are detailed in our clinical review on hydrocolloid dressing for bed sores.
  • Venous Stasis Ulcers: Chronic lower-extremity venous ulcers with controlled exudate levels, frequently used beneath multi-layer compression bandage systems.
  • Arterial and Neuropathic Ulcers: Shallow ischemic or diabetic neurotrophic foot ulcers exhibiting moist granulation without signs of active spreading infection.
  • Donor Sites and Graft Locations: Split-thickness skin graft donor sites, where the occlusive moist environment accelerates re-epithelialization and reduces post-operative pain.
  • Superficial Burns: First-degree burns and partial-thickness second-degree thermal burns with intact or deroofed blister bases.
  • Post-Surgical and Traumatic Wounds: Clean post-operative surgical incisions, superficial lacerations, and dermal abrasions.

Contraindications and Safety Warnings

Manufacturer instructions for use define specific absolute contraindications where hydrocolloid dressings must not be used:

  • Full-Thickness Third-Degree Burns: Tegasorb is strictly contraindicated for full-thickness third-degree burns involving subcutaneous tissue, fascia, or muscle, which require surgical debridement and specialized graft coverage.
  • Known Chemical Hypersensitivity: The dressing should not be used on patients with a documented allergy or severe hypersensitivity to hydrocolloid polymers, sodium carboxymethylcellulose, or polyurethane adhesive components.

Clinical Precautions and Infection Management

Hydrocolloid dressings are contraindicated as a primary treatment for heavily draining, exudative wounds. When applied to wounds with copious drainage, the absorption capacity of the hydrocolloid matrix is rapidly exceeded, leading to pooling of wound fluid under the dressing and extensive maceration of periwound skin. Furthermore, because Tegasorb forms an occlusive seal that limits oxygen penetration, it should not be applied to wounds with active, untreated anaerobic infections. If a clinical wound exhibits signs of active spreading infection (such as pronounced periwound erythema, induration, systemic fever, or purulence), occlusive hydrocolloid therapy must be discontinued until the infection is evaluated by a physician and treated with appropriate systemic antimicrobials and non-occlusive dressings.

CMS Reimbursement, HCPCS Coding, and DME MAC Guidelines

For outpatient wound clinics, durable medical equipment (DME) suppliers, and institutional procurement departments across the United States, proper billing and utilization of Tegasorb depends on compliance with Centers for Medicare and Medicaid Services (CMS) coverage policies. Coverage for surgical dressings is governed by the DME Medicare Administrative Contractor (MAC) Local Coverage Determination (LCD) L33831 and its associated Policy Article A54563.

Pad Size Measurement Rule

A frequent error in surgical dressing billing involves calculating surface area based on the total product footprint rather than the absorbent pad. Under CMS DME MAC billing instructions, the Healthcare Common Procedure Coding System (HCPCS) code assignment for hydrocolloid wound covers is determined strictly by the dimensions of the inner absorbent hydrocolloid pad, excluding any extended adhesive tape or transparent film borders. For example, catalog number 90001 features an inner hydrocolloid pad measuring 2.75 inches by 3.5 inches, yielding a pad surface area of 9.6 square inches. Even though the overall dressing with its film border measures 4 inches by 4.75 inches (19 square inches), it bills under code A6237 (pad 16 square inches or less, with border), not the higher-tier code A6238.

Primary HCPCS Codes Applicable to Tegasorb

The Tegasorb line maps directly into five primary HCPCS billing codes based on shape, border presence, and pad surface area:

  • A6234: Hydrocolloid dressing, wound cover, sterile, pad size 16 square inches or less, without adhesive border, each dressing. Covers 4″ x 4″ square non-bordered dressings such as catalog numbers 90002 and 90022.
  • A6235: Hydrocolloid dressing, wound cover, sterile, pad size more than 16 square inches but less than or equal to 48 square inches, without adhesive border, each dressing. Covers 6″ x 6″ square non-bordered dressings such as catalog number 90005.
  • A6237: Hydrocolloid dressing, wound cover, sterile, pad size 16 square inches or less, with adhesive border, each dressing. Covers bordered oval styles with small pads such as catalog numbers 90001 and 90021.
  • A6238: Hydrocolloid dressing, wound cover, sterile, pad size more than 16 square inches but less than or equal to 48 square inches, with adhesive border, each dressing. Covers bordered oval styles with medium-to-large pads (90003, 90004, 90023, 90024) and the sacral bordered dressing (90007).
  • A6239: Hydrocolloid dressing, wound cover, sterile, pad size more than 48 square inches, with adhesive border, each dressing. Reserved for extra-large wound cover pads.

Qualifying Wound Criteria and Utilization Limits

Medicare reimbursement under LCD L33831 requires that dressings be prescribed for a “qualifying wound.” By statutory definition, a qualifying wound must either be caused or treated by a surgical procedure, or have undergone documented debridement (surgical, mechanical, enzymatic, or autolytic) performed by a licensed healthcare clinician. Dressings utilized on intact skin for purely preventative purposes are non-covered by Medicare Part B DME benefits.

Furthermore, LCD L33831 establishes clear utilization parameters for hydrocolloids. Because hydrocolloid dressings are designed for extended multi-day wear, Medicare allows a standard dressing change frequency of up to three times per week. Claims billing for daily changes will be audited and denied as medically unnecessary unless detailed clinical records justify unusual exudate levels or dressing compromise. Additionally, when a bordered hydrocolloid dressing (A6237 or A6238) is billed, Medicare considers secondary retention tape to be bundled into the dressing; billing separate tape codes for bordered dressings is disallowed.

Sourced Comparative Analysis: Hydrocolloids vs. Modern Alternatives

Selecting the optimal dressing category requires clinical staff and buyers to balance exudate handling capacity, wear duration, autolytic potential, and cost. While Tegasorb hydrocolloids remain an essential standard for light-to-moderate drainage and shear protection, other dressing classes provide superior performance in specific clinical scenarios.

The comparative matrix below evaluates Tegasorb hydrocolloids against three common alternative advanced dressing categories: polyurethane silicone foams, calcium alginates, and transparent polyurethane film dressings.

Clinical Parameter Tegasorb Hydrocolloid Silicone Foam (e.g., Mepilex) Calcium Alginate Transparent Film (Tegaderm)
Absorption Capacity Low to moderate (swells to gel) Moderate to high (vertical wicking) Very high (absorbs 15x–20x weight) None (moisture vapor permeable only)
Moist Healing Environment High (occlusive moisture seal) High (maintains hydration balance) High (forms sodium-calcium gel) Moderate (traps transudate)
Autolytic Debridement Excellent (locks in enzymes) Moderate (absorptive focus) Good (supports moist debridement) Good (autolytic for shallow dry slough)
Typical Wear Duration 3 to 7 days 3 to 7 days 1 to 3 days (requires cover) 3 to 7 days
Periwound Maceration Risk High if exudate is heavy Low (protects periwound skin) Low (vertical absorption prevents spread) High if exudate accumulates
Primary Role in Practice Shallow ulcers, shear protection Moderately-to-heavy exuding wounds Heavily draining cavities and sinus tracts Catheter sites, intact skin tears

When managing moderately to heavily exuding wounds, polyurethane foam dressings frequently outperform hydrocolloids because their open-cell structure wicks fluid away from the periwound skin, minimizing the risk of epidermal maceration. For a direct clinical evaluation of how hydrocolloids compare with modern silicone foam technology, consult our head-to-head comparison of DuoDERM vs Mepilex. In addition, an in-depth breakdown of foam construction and border adhesives is available in our overview of silicone foam wound dressings.

Application Protocol, Wear Time, and Safe Removal Guidelines

Proper clinical handling ensures that Tegasorb delivers maximum barrier protection, remains securely adhered, and is removed without causing skin trauma.

Pre-Application Preparation and Sizing

Before applying the dressing, the wound bed should be cleansed using sterile saline or an approved non-cytotoxic wound cleanser and gently patted dry. The periwound skin must be thoroughly dried and free from oils, moisturizers, or residual cleansing solutions that could compromise adhesive bonding. When selecting dressing size, clinicians should ensure that the hydrocolloid pad extends at least 1 inch (2.5 cm) beyond the perimeter of the wound onto healthy, intact skin. This overlap provides adequate anchor surface and ensures that the expanding gel bubble does not prematurely breach the dressing margins.

Monitoring and Extended Wear Time

Tegasorb dressings are engineered to remain in place for up to 7 calendar days depending on the volume of exudate produced by the wound. Rather than changing dressings on an arbitrary daily schedule, clinical guidelines recommend changing Tegasorb based on physiological indicators. As wound exudate is absorbed, a noticeable whitish, gelatinous blister or “gel bubble” forms beneath the dressing over the wound bed. This blister indicates active fluid absorption. The dressing should be changed when this gel bubble expands to within approximately 0.5 inches (1 cm) of the dressing border, or immediately if the edge lifts, leaks, or becomes detached.

Atraumatic Removal Protocol

Removing hydrocolloids improperly by peeling them upward at a 90-degree angle can cause severe epidermal stripping, particularly in elderly patients with fragile tissue. Clinicians and caregivers should follow the “stretch-release” technique:

  1. Press down gently on the intact periwound skin with one hand to stabilize the tissue.
  2. With the other hand, carefully lift one corner of the outer film border.
  3. Gently stretch the dressing horizontally along the plane of the skin, pulling parallel to the surface rather than peeling away vertically. This stretching action elongates the adhesive polymer chains, causing them to release cleanly from the epidermis without shearing epidermal cells.
  4. Work around the perimeter toward the center until the dressing releases freely from the wound bed.

Upon removal, clinicians will observe a characteristic yellowish, gelatinous residue in the wound bed accompanied by a distinct, mildly pungent odor. This appearance is completely normal and represents the hydrated sodium carboxymethylcellulose and pectin components, not purulent wound infection. The residue should be gently irrigated away with warm sterile saline prior to evaluating the underlying granulation tissue.

Common Misunderstandings in Clinical Supply and Practice

Several persistent misunderstandings surrounding hydrocolloid dressings lead to procurement errors, clinical misdiagnoses, and unnecessary dressing changes:

  • Confusing Tegasorb with Transparent Film: Procurement staff frequently confuse 3M Tegasorb with standard 3M Tegaderm transparent film. While both products share an identical polyurethane outer backing, transparent film contains no absorbent hydrocolloid pad and has zero fluid absorption capacity. Applying transparent film to an exuding dermal ulcer results in rapid fluid pooling, periwound maceration, and skin breakdown.
  • The “Gel Bubble as Infection” Error: Inexperienced healthcare staff and family caregivers often mistake the soft, yellowish gel bubble and odor produced by hydrated hydrocolloids for an acute purulent abscess. This misinterpretation frequently results in premature dressing removal and inappropriate requests for topical or systemic antibiotics. If the yellowish material rinses away easily with saline irrigation leaving clean granulation tissue without surrounding erythema or fever, it is harmless hydrocolloid residue.
  • Applying Hydrocolloids to Heavy Exudate: Using hydrocolloids on heavily exuding venous ulcers or deep surgical cavities is a common clinical error. When exudate overwhelms the pad, fluid leaks onto the periwound skin, dissolving the epidermal stratum corneum and causing severe maceration. Heavily draining wounds require alginate or foam primary dressings.
  • Billing HCPCS Based on Total Border Dimensions: As noted in Medicare guidelines, billing DME claims based on the total border dimensions of bordered dressings (e.g., billing 90001 under A6238 instead of A6237) is an audit violation. Billing departments must strictly verify the inner pad dimensions before submitting claims.
  • Ordering Unnecessary Secondary Tape: Purchasing staff often bundle rolls of medical adhesive tape with bordered Tegasorb orders. Under CMS LCD rules, secondary retention tape is considered medically unnecessary over bordered dressings and is denied for separate reimbursement.

Practical Scenarios for Procurement, Research Clinics, and Supply Staff

To contextualize procurement specifications and clinical stocking decisions, consider the following practical scenarios:

Scenario 1: Long-Term Care Pressure Injury Prevention and Staging Protocol

A skilled nursing facility seeks to standardize its wound formulary for bedbound residents. The facility wound team establishes a dual-tier stocking protocol: Tegasorb Thin (catalog 90022 and 90023) is designated for proactive friction protection on intact, reddened heels and elbows showing early signs of shear stress (Stage I pressure injury risk). Concurrently, standard bordered oval Tegasorb (90003) and sacral contoured dressings (90007) are stocked for residents with verified Stage II sacral and trochanteric pressure ulcers with light-to-moderate drainage, enabling multi-day wear and reducing supply change labor.

Scenario 2: Outpatient Wound Care Center Formulary Rationalization

An outpatient clinic treating diabetic foot ulcers and venous stasis ulcers conducts an annual review of its surgical dressing inventory. To eliminate billing audit exposure, the clinic’s procurement coordinator cross-references all 3M catalog items against CMS LCD L33831 pad area thresholds. The team ensures that all bordered oval dressings are mapped accurately to A6237 and A6238 based on inner pad area, updates EHR electronic order sets to eliminate automatic secondary tape requests for bordered items, and establishes an algorithmic rule directing clinicians to silicone foams whenever wound drainage exceeds moderate levels.

Scenario 3: Clinical Research Trial Protocol Standardization

A multi-center clinical research study evaluating surgical site healing following donor skin harvesting requires a standardized, moisture-retentive dressing regimen across five trial sites. The study protocol specifies Tegasorb Regular square sheets (90002) for donor sites, citing the extensive peer-reviewed literature validating autolytic debridement and rapid re-epithelialization beneath sodium carboxymethylcellulose matrices. Study monitors verify that each clinical site receives identical 4″ x 4″ packaging lots, ensuring uniformity in dressing changes and fluid management metrics across the trial cohort.

Frequently asked questions

What is the difference between Tegasorb and Tegaderm?

Tegasorb is an absorbent hydrocolloid wound dressing that incorporates a thick inner pad made of sodium carboxymethylcellulose, pectin, and elastomeric polymers designed to absorb exudate and form a soothing gel. Tegaderm, in its primary form, refers to a thin, non-absorbent transparent polyurethane film used primarily for securing intravenous catheters and protecting dry, superficial wounds. While Tegasorb utilizes Tegaderm film as its outer water-resistant backing, standard Tegaderm film does not contain an absorbent hydrocolloid pad.

How often should a Tegasorb dressing be changed?

Tegasorb can remain in place for up to 7 days depending on the volume of wound exudate. Clinicians should change the dressing when the whitish gel bubble expands to within approximately 0.5 inches (1 cm) of the pad margin, or sooner if the outer adhesive edge begins to curl, lift, or leak fluid. Medicare coverage guidelines allow a change frequency of up to 3 times per week for outpatient reimbursement.

Why does Tegasorb produce a yellowish gel and odor upon removal?

The yellowish gel and mild, distinctive odor observed upon removing Tegasorb are normal physical results of the hydrocolloid polymers interacting with wound fluid. As the sodium carboxymethylcellulose and pectin particles absorb exudate, they break down into a viscous, cohesive gel sheet. This material should not be confused with purulence or wound infection; it rinses away cleanly with sterile saline irrigation.

Can Tegasorb be used on infected wounds?

Tegasorb should not be used as a primary dressing on actively infected wounds, particularly those with suspected anaerobic bacterial involvement. Because hydrocolloid dressings create an occlusive, low-oxygen microenvironment, they can encourage anaerobic bacterial proliferation. If an infected wound requires treatment, it must be managed under direct physician supervision using appropriate systemic antimicrobial therapy and non-occlusive dressings.

Which HCPCS billing codes apply to 3M Tegasorb dressings?

Tegasorb dressings bill under Medicare HCPCS codes A6234 (pad 16 sq. in. or less, without border), A6235 (pad 16 to 48 sq. in., without border), A6237 (pad 16 sq. in. or less, with border), and A6238 (pad 16 to 48 sq. in., with border). Code selection is based strictly on the dimensions and surface area of the inner hydrocolloid pad, not the outer film border.

Can Tegasorb be cut to size?

Square, non-bordered Tegasorb dressings (such as catalog numbers 90002, 90005, and 90022) can be safely cut using sterile medical scissors to fit irregular anatomical locations. However, bordered oval styles (such as 90001 and 90003) and sacral dressings should not be cut, as trimming compromises the integrated adhesive film border, disrupts the moisture seal, and increases the risk of edge leakage.

Sources

  • U.S. Food and Drug Administration. (1998-10-26). 510(k) Premarket Notification K982893: 3M Tegasorb Hydrocolloid Dressing. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K982893 (accessed 2026-11-14)
  • U.S. Food and Drug Administration. (1998-10-26). 510(k) Premarket Notification K982892: 3M Tegasorb Thin Hydrocolloid Dressing. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K982892 (accessed 2026-11-14)
  • Centers for Medicare & Medicaid Services. (2024-01-01). Local Coverage Determination (LCD) L33831: Surgical Dressings. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33831 (accessed 2026-11-14)
  • 3M Health Care / Solventum. (2024-05-15). 3M Tegaderm Hydrocolloid Dressing Product Profile and Instructions for Use. https://www.3m.com (accessed 2026-11-14)
  • Thomas, S. (2000-06-08). 3M Tegasorb Thin: a hydrocolloid dressing for chronic wounds. British Journal of Nursing, 9(11), 711-714. https://pubmed.ncbi.nlm.nih.gov/11235265/ (accessed 2026-11-14)
  • Belmin, J., et al. (2000-11-01). A comparison of two hydrocolloid sheet dressings. British Journal of Community Nursing, 5(11), 567-573. https://pubmed.ncbi.nlm.nih.gov/12066057/ (accessed 2026-11-14)

Data: 3M Tegasorb Hydrocolloid Dressing Product Specifications and HCPCS Crosswalk

Sourced specifications for 3M Tegasorb and Tegasorb Thin hydrocolloid wound dressings, compiling catalog numbers, shapes, dimensions, pad surface areas, packaging units, and CMS HCPCS reimbursement codes from FDA 510(k) clearances and manufacturer labeling.

3M Tegasorb Hydrocolloid Dressing Product Specifications and HCPCS Crosswalk
Catalog ItemProduct LineShape and ConfigurationPad Dimensions (inches)Pad Area (sq in)Overall Dimensions (inches)HCPCS CodeBox Quantity (dressings)
90001Tegasorb RegularOval with border2.75 x 3.59.64 x 4.75A62375
90002Tegasorb RegularSquare without border4 x 4164 x 4A62345
90003Tegasorb RegularOval with border4 x 4.75195.25 x 6A62385
90004Tegasorb RegularOval with border5.5 x 6.7537.16.75 x 8A62385
90005Tegasorb RegularSquare without border6 x 6366 x 6A62355
90007Tegasorb RegularSacral with border4.9 x 5.5276.4 x 6.7A62386
90021Tegasorb ThinOval with border2.75 x 3.59.64 x 4.75A623710
90022Tegasorb ThinSquare without border4 x 4164 x 4A623410
90023Tegasorb ThinOval with border4 x 4.75195.25 x 6A623810
90024Tegasorb ThinOval with border5.5 x 6.7537.16.75 x 8A623810

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Tegasorb: 3M Hydrocolloid Dressing Guide & Specs

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →